Exercising Best Practices in Familial Hypercholesterolemia An Interactive Journey

Robert S. Rosenson, MD

This activity is jointly provided by Global Education Group and Integritas Communications.


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.


This activity is co-sponsored by the Family Heart Foundation.

Program Overview 

Familial hypercholesterolemia (FH) is a genetic disorder marked by high levels of circulating low-density lipoprotein cholesterol (LDL-C), leading to increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Individuals with FH frequently remain undiagnosed, resulting in poor outcomes and failure to diagnose family members. Once diagnosed, the preferred treatment options can vary based on FH genotype, as well as baseline and target LDL-C levels. Therefore, best practices for the use of these therapies, including placement within treatment algorithms, comprise an important aspect of management. This CME Circuit Training™ activity utilizes a unique multimedia platform that consists of three 10-minute circuits that will boost your endurance and strengthen your expertise within the diagnosis and management of FH.

Target Audience 

The educational design of this activity addresses the needs of lipidologists, cardiologists, pediatricians, primary care physicians (PCPs), and other clinicians involved in the identification and/or management of adult or pediatric patients with FH. 

Educational Objectives  

After completing this activity, the participant should be better able to: 

  • Discuss FH pathophysiology, inducing clinical burdens, genetic causes, and implications for treatment
  • Evaluate patients with suspected FH for clinical manifestations, cardiovascular risk, family history, and, when necessary, referrals for genetic analyses and cascade screening
  • Describe the clinical profiles and recent trial evidence for current biologic therapies in FH, including homozygous disease
  • Construct lipid-lowering regimens for pediatric and adult patients with homozygous or heterozygous FH to reflect disease subtype, potential risks, hypercholesterolemia severity, and treatment history


Robert S Rosenson, MD 
Director, Lipids and Metabolism 
Mount Sinai Health System 
Professor of Medicine (Cardiology) 
Icahn School of Medicine at Mount Sinai 
New York, New York 

Physician Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation 

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions to Receive Credit

In order to receive credit, participants must complete the following: 

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity. 
  2. Complete the Preactivity Questions. 
  3. Review the activity content. 
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation. 

Global Contact Information 

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Fee Information & Refund/Cancellation Policy 

There is no fee for this educational activity. 

Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies: 

Robert S. Rosenson, MD:  Consulting Fee(s): Amgen, Arrowhead, CRISPER Therapeutics, Eli Lilly, Novartis, Precision Biosciences, Regeneron, Verve Therapeutics, UltraGenyx; Contracted Research: Amgen, Arrowhead, Eli Lilly, Novartis, Regeneron; Honoraria: Amgen, Kowa, Regeneron; Stock option holder: MediMergent, LLC; Royalty: Wolters Kluwer (UpToDate)

The Global and Integritas Communications planners and managers have nothing to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.50

credit type CME

release 02/28/2023

expiration 02/28/2024